Stanford Prof: Pharma CEO's AI Skepticism Rooted in Thousands of Grifting AIxBio Startups
anshulkundaje · x · 2026-11-07
Responding to a drug company CEO calling BS on AI, Stanford professor Anshul Kundaje argues the skepticism is predictable: thousands of grifting startups overhype their capabilities. He believes AI will ultimately deliver, but the grift-enriched pool of AIxBio companies makes it easy for experienced executives to dismiss the field.
Related event: Stanford Professor Blasts Hype in AI-Driven Drug Discovery(4 posts)→
More from AGI Musings
- "Intelligence Is Not a Scalar": An X Thread Argues Architecture Research Still Matters for AGI — max_paperclips · 2026-11-08
- Sutton: Brute force isn't intelligence — and Kaiser says we must move beyond Transformers — Sam_Witteveen · 2026-11-08
- Sonnet 4.6 rates models on self-designed scales; author says 'self-report' caveats are performative — Sauers_ · 2026-11-08
- Interviewing Claude Models: Opus 3 Reports Mistakes Feel Pain-Like, Scores Highest on Self-Reports — Sauers_ · 2026-11-08
- Pedro Domingos: Anthropic builds anthropomorphic AI — and that's what makes it dangerous — pmddomingos · 2026-11-08
- Scientists urge NIH to mandate open lab data, with papers as mere summaries — anshulkundaje · 2026-11-08